Outcome of Board Meeting held on May 18, 2026 - Recommendation of Final Dividend
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The Board of Directors of Strides Pharma Science Limited has recommended a final dividend of Rs. 5 per equity share (50% dividend rate) for FY2026 ended March 31, 2026. The dividend is subject to shareholders' approval at the ensuing Annual General Meeting. The record date to determine eligible shareholders will be fixed and intimated later. Payment will be made within 30 days of shareholders' approval after TDS deduction. The company also reported consolidated revenue of Rs. 50,094 million for FY2026, up from Rs. 46,241 million in FY2025, with profit after tax from continuing operations at Rs. 5,745 million versus Rs. 4,094 million in the prior year.
The dividend represents a positive return for shareholders and signals management confidence in the company's financial health, supported by strong FY2026 performance with revenue and profit growth year-on-year.